Ra Pharmaceuticals, Inc. (RARX) EPS Estimated At $-0.72; OTSUKA HOLDINGS COMPANY L (OTSKF) Shorts Increased By 27.46%

February 18, 2018 - By Ellis Scott

OTSUKA HOLDINGS COMPANY L (OTCMKTS:OTSKF) had an increase of 27.46% in short interest. OTSKF’s SI was 963,500 shares in February as released by FINRA. Its up 27.46% from 755,900 shares previously. With 300 avg volume, 3212 days are for OTSUKA HOLDINGS COMPANY L (OTCMKTS:OTSKF)’s short sellers to cover OTSKF’s short positions. The stock increased 7.17% or $3.16 during the last trading session, reaching $47.21. About 120 shares traded. Otsuka Holdings Co., Ltd. (OTCMKTS:OTSKF) has 0.00% since February 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect Ra Pharmaceuticals, Inc. (NASDAQ:RARX) to report $-0.72 EPS on March, 5.They anticipate $0.01 EPS change or 1.37% from last quarter’s $-0.73 EPS. After having $-0.68 EPS previously, Ra Pharmaceuticals, Inc.’s analysts see 5.88% EPS growth. The stock increased 0.59% or $0.04 during the last trading session, reaching $6.83. About 191,814 shares traded. Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has 0.00% since February 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Otsuka Holdings Co., Ltd., together with its subsidiaries, operates in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company has market cap of $24.64 billion. The companyÂ’s Pharmaceutical segment provides healthcare solutions in the areas of central nervous system and neurology, oncology, cardiovascular and renal system, gastroenterology, respiratory system, infectious disease, ophthalmology, dermatology, allergies, urology, and others. It has a 24.31 P/E ratio. This segment also offers intravenous solutions, enteral nutrition, and contract manufacturing services; influenza diagnostic agents, Helicobacter pylori test kits, and other products; and apheresis device for leukocyte adsorption, drug-eluting stents, spinal devices, and other products.

Among 3 analysts covering Ra Pharmaceuticals (NASDAQ:RARX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ra Pharmaceuticals had 5 analyst reports since August 24, 2017 according to SRatingsIntel. The stock of Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has “Buy” rating given on Tuesday, October 24 by RBC Capital Markets. Jefferies maintained the shares of RARX in report on Thursday, August 24 with “Buy” rating. On Tuesday, September 26 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by Credit Suisse on Friday, November 10 with “Outperform”.

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company has market cap of $154.54 million. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. It currently has negative earnings. The Company’s lead product candidate is RA101495, an injection into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria , as well as for the treatment of other debilitating complement-mediated diseases, including refractory generalized myasthenia gravis (rMG) and lupus nephritis (LP).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: